CoChat

Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target

Open access
Kolluri, Siva Kumar, Jin, Un-Ho, Safe, Stephen · 2017 · Archives of Toxicology
Cited by 173

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

The aryl hydrocarbon receptor (AhR) was initially identified as the receptor that binds and mediates the toxic effects induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and structurally related halogenated aromatics. Other toxic compounds including some polynuclear aromatic hydrocarbons act through the AhR; however, during the last 25 years, it has become apparent that the AhR plays an essential role in maintaining cellular homeostasis. Moreover, the scope of ligands that bind the AhR includes endogenous compounds such as multiple tryptophan metabolites, other endogenous biochemicals, pharmaceuticals and health-promoting phytochemicals including flavonoids, indole-3-carbinol and its metabolites. It has also been shown that like other receptors, the AhR is a drug target for multiple diseases including cancer, where both AhR agonists and antagonists effectively block many of the critical hallmarks of cancer in multiple tumor types. This review describes the anti-cancer activities of AhR ligands and demonstrates that it is time to separate the AhR from TCDD and exploit the potential of the AhR as a novel target for cancer chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00204-017-1981-2

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 151

  1. Aesoy R, Clyne CD, Chand AL (2015) Insights into orphan nuclear receptors as prognostic markers and novel therapeutic targets for breast cancer. Front Endocrinol 6:115. doi: 10.3389/fendo.2015.00115 · DOI
  2. American Cancer Society (2016) Cancer facts and figures 2016. American Cancer Society, Atlanta
  3. Andersson P, Rubio C, Poellinger L, Hanberg A (2005) Gastric hamartomatous tumours in a transgenic mouse model expressing an activated dioxin/Ah receptor. Anticancer Res 25(2A):903–911
  4. Baek SH, Kim KI (2014) Emerging roles of orphan nuclear receptors in cancer. Annu Rev Physiol 76:177–195. doi: 10.1146/annurev-physiol-030212-183758 · DOI
  5. Bambury RM, Scher HI (2015) Enzalutamide: development from bench to bedside. Urol Oncol 33(6):280–288. doi: 10.1016/j.urolonc.2014.12.017 · DOI
  6. Barhoover MA, Hall JM, Greenlee WF, Thomas RS (2010) Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4. Mol Pharmacol 77(2):195–201. doi: 10.1124/mol.109.059675 · DOI
  7. Barnes-Ellerbe S, Knudsen KE, Puga A (2004) 2,3,7,8-Tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. Mol Pharmacol 66(3):502–511. doi: 10.1124/mol.104.000356 · DOI
  8. Becker RA, Patlewicz G, Simon TW, Rowlands JC, Budinsky RA (2015) The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor. Regul Toxicol Pharmacol 73(1):172–190. doi: 10.1016/j.yrtph.2015.06.015 · DOI
  9. Benson JM, Shepherd DM (2011) Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn’s disease. Toxicol Sci 120(1):68–78. doi: 10.1093/toxsci/kfq360 · DOI · Paper page
  10. Bock KW (2017) From dioxin toxicity to putative physiologic functions of the human Ah receptor in homeostasis of stem/progenitor cells. Biochem Pharmacol 123:1–7. doi: 10.1016/j.bcp.2016.06.015 · DOI
  11. Bock KW, Kohle C (2005) Ah receptor- and TCDD-mediated liver tumor promotion: clonal selection and expansion of cells evading growth arrest and apoptosis. Biochem Pharmacol 69(10):1403–1408. doi: 10.1016/j.bcp.2005.02.004 · DOI
  12. Boitano AE, Wang J, Romeo R et al (2010) Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329(5997):1345–1348. doi: 10.1126/science.1191536 · DOI · Paper page
  13. Brinkman AM, Wu J, Ersland K, Xu W (2014) Estrogen receptor alpha and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells. BMC Cancer 14:344. doi: 10.1186/1471-2407-14-344 · DOI
  14. Bruera G, Cannita K, Giordano AV et al (2014) Multidisciplinary management of hepatocellular carcinoma in clinical practice. Biomed Res Int 2014:806391. doi: 10.1155/2014/806391 · doi:10.1155/2014/806391
  15. Bunaciu RP, Yen A (2011) Activation of the aryl hydrocarbon receptor AhR promotes retinoic acid-induced differentiation of myeloblastic leukemia cells by restricting expression of the stem cell transcription factor Oct4. Cancer Res 71(6):2371–2380. doi: 10.1158/0008-5472.CAN-10-2299 · DOI · Paper page
  16. Burris TP, Solt LA, Wang Y et al (2013) Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev 65(2):710–778. doi: 10.1124/pr.112.006833 · DOI · Paper page
  17. Callero MA, Suarez GV, Luzzani G, Itkin B, Nguyen B, Loaiza-Perez AI (2012) Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment. Int J Oncol 41(1):125–134. doi: 10.3892/ijo.2012.1427 · DOI
  18. Casado FL, Singh KP, Gasiewicz TA (2011) Aryl hydrocarbon receptor activation in hematopoietic stem/progenitor cells alters cell function and pathway-specific gene modulation reflecting changes in cellular trafficking and migration. Mol Pharmacol 80(4):673–682. doi: 10.1124/mol.111.071381 · DOI
  19. Chang JT, Chang H, Chen PH, Lin SL, Lin P (2007) Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 13(1):38–45. doi: 10.1158/1078-0432.CCR-06-1166 · DOI
  20. Chen I, McDougal A, Wang F, Safe S (1998) Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 19:1631–1639 · DOI · Paper page
  21. Cheng YH, Huang SC, Lin CJ, Cheng LC, Li LA (2012) Aryl hydrocarbon receptor protects lung adenocarcinoma cells against cigarette sidestream smoke particulates-induced oxidative stress. Toxicol Appl Pharmacol 259(3):293–301. doi: 10.1016/j.taap.2012.01.005 · DOI
  22. Cheng J, Li W, Kang B et al (2015) Tryptophan derivatives regulate the transcription of Oct4 in stem-like cancer cells. Nat Commun 6:7209. doi: 10.1038/ncomms8209 · DOI
  23. Chuang CY, Chang H, Lin P et al (2012) Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer. Gene 492(1):262–269. doi: 10.1016/j.gene.2011.10.019 · DOI
  24. Collins JJ, Bodner K, Aylward LL, Wilken M, Bodnar CM (2009) Mortality rates among trichlorophenol workers with exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Am J Epidemiol 170(4):501–506. doi: 10.1093/aje/kwp153 · doi:10.1093/aje/kwp153
  25. Contador-Troca M, Alvarez-Barrientos A, Barrasa E et al (2013) The dioxin receptor has tumor suppressor activity in melanoma growth and metastasis. Carcinogenesis 34(12):2683–2693. doi: 10.1093/carcin/bgt248 · DOI · Paper page
  26. de Tomaso Portaz AC, Caimi GR, Sanchez M et al (2015) Hexachlorobenzene induces cell proliferation, and aryl hydrocarbon receptor expression (AhR) in rat liver preneoplastic foci, and in the human hepatoma cell line HepG2. AhR is a mediator of ERK1/2 signaling, and cell cycle regulation in HCB-treated HepG2 cells. Toxicology 336:36–47. doi: 10.1016/j.tox.2015.07.013 · DOI
  27. Dever DP, Opanashuk LA (2012) The aryl hydrocarbon receptor contributes to the proliferation of human medulloblastoma cells. Mol Pharmacol 81(5):669–678. doi: 10.1124/mol.111.077305 · DOI
  28. Dewa Y, Nishimura J, Jin M et al (2009) Molecular expression analysis of beta-naphthoflavone-induced hepatocellular tumors in rats. Toxicol Pathol 37(4):446–455. doi: 10.1177/0192623309335062 · DOI
  29. Diaz-Diaz CJ, Ronnekleiv-Kelly SM, Nukaya M et al (2016) The aryl hydrocarbon receptor is a repressor of inflammation-associated colorectal tumorigenesis in mouse. Ann Surg 264(3):429–436. doi: 10.1097/SLA.0000000000001874 · DOI · Paper page
  30. DiNatale BC, Schroeder JC, Perdew GH (2011) Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines. Mol Carcinog 50(3):173–183. doi: 10.1002/mc.20702 · DOI
  31. DiNatale BC, Smith K, John K, Krishnegowda G, Amin SG, Perdew GH (2012) Ah receptor antagonism represses head and neck tumor cell aggressive phenotype. Mol Cancer Res 10(10):1369–1379. doi: 10.1158/1541-7786.MCR-12-0216 · DOI · Paper page
  32. Ehrlich AK, Pennington JM, Wang X et al (2016) Activation of the aryl hydrocarbon receptor by 10-Cl-BBQ prevents insulitis and effector T cell development independently of Foxp3+ regulatory T cells in nonobese diabetic mice. J Immunol 196(1):264–273. doi: 10.4049/jimmunol.1501789 · DOI
  33. Esser C (2012) Biology and function of the aryl hydrocarbon receptor: report of an international and interdisciplinary conference. Arch Toxicol 86(8):1323–1329. doi: 10.1007/s00204-012-0818-2 · DOI
  34. Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A (2010) The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res 70(1):212–220. doi: 10.1158/0008-5472.CAN-09-3090 · DOI · Paper page
  35. Ferdinand R, Mitchell SA, Batson S, Tumur I (2012) Treatments for chronic myeloid leukemia: a qualitative systematic review. J Blood Med 3:51–76. doi: 10.2147/JBM.S33380 · DOI · Paper page
  36. Fernandez-Salguero P, Hilbert DM, Rudikoff S, Ward JM, Gonzalez FJ (1996) Aryl hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol 140:173–179 · DOI · Paper page
  37. Fritz WA, Lin TM, Cardiff RD, Peterson RE (2007) The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 28(2):497–505. doi: 10.1093/carcin/bgl179 · DOI
  38. Fritz WA, Lin TM, Safe S, Moore RW, Peterson RE (2009) The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem Pharmacol 77(7):1151–1160. doi: 10.1016/j.bcp.2008.12.015 · DOI · Paper page
  39. Fukasawa K, Kagaya S, Maruyama S et al (2015) A novel compound, NK150460, exhibits selective antitumor activity against breast cancer cell lines through activation of aryl hydrocarbon receptor. Mol Cancer Ther 14(2):343–354. doi: 10.1158/1535-7163.MCT-14-0158 · DOI
  40. Gluschnaider U, Hidas G, Cojocaru G, Yutkin V, Ben-Neriah Y, Pikarsky E (2010) beta-TrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. PLoS ONE 5(2):e9060. doi: 10.1371/journal.pone.0009060 · DOI
  41. Goode GD, Ballard BR, Manning HC, Freeman ML, Kang Y, Eltom SE (2013) Knockdown of aberrantly upregulated aryl hydrocarbon receptor reduces tumor growth and metastasis of MDA-MB-231 human breast cancer cell line. Int J Cancer 133(12):2769–2780. doi: 10.1002/ijc.28297 · DOI
  42. Gramatzki D, Pantazis G, Schittenhelm J et al (2009) Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene 28(28):2593–2605. doi: 10.1038/onc.2009.104 · DOI
  43. Gu A, Ji G, Jiang T et al (2012) Contributions of aryl hydrocarbon receptor genetic variants to the risk of glioma and PAH-DNA adducts. Toxicol Sci 128(2):357–364. doi: 10.1093/toxsci/kfs158 · DOI
  44. Haggiag S, Ruggieri S, Gasperini C (2013) Efficacy and safety of laquinimod in multiple sclerosis: current status. Ther Adv Neurol Disord 6(6):343–352. doi: 10.1177/1756285613499424 · DOI
  45. Hall JM, Barhoover MA, Kazmin D, McDonnell DP, Greenlee WF, Thomas RS (2010) Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol Endocrinol 24(2):359–369. doi: 10.1210/me.2009-0346 · DOI · Paper page
  46. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70 · DOI · Paper page
  47. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi: 10.1016/j.cell.2011.02.013 · DOI · Paper page
  48. Hanieh H (2015) Aryl hydrocarbon receptor-microRNA-212/132 axis in human breast cancer suppresses metastasis by targeting SOX4. Mol Cancer 14:172. doi: 10.1186/s12943-015-0443-9 · DOI
  49. Haque M, Francis J, Sehgal I (2005) Aryl hydrocarbon exposure induces expression of MMP-9 in human prostate cancer cell lines. Cancer Lett 225(1):159–166. doi: 10.1016/j.canlet.2004.11.043 · DOI
  50. Harrill JA, Parks BB, Wauthier E, Rowlands JC, Reid LM, Thomas RS (2015) Lineage-dependent effects of aryl hydrocarbon receptor agonists contribute to liver tumorigenesis. Hepatology 61(2):548–560. doi: 10.1002/hep.27547 · DOI
  51. Hayashibara T, Yamada Y, Mori N et al (2003) Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem Biophys Res Commun 300(1):128–134 · DOI
  52. Helsen C, Van den Broeck T, Voet A et al (2014) Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer 21(4):T105–T118. doi: 10.1530/ERC-13-0545 · DOI
  53. Hruba E, Vondracek J, Libalova H et al (2011) Gene expression changes in human prostate carcinoma cells exposed to genotoxic and nongenotoxic aryl hydrocarbon receptor ligands. Toxicol Lett 206(2):178–188. doi: 10.1016/j.toxlet.2011.07.011 · DOI
  54. Hsu EL, Yoon D, Choi HH et al (2007) A proposed mechanism for the protective effect of dioxin against breast cancer. Toxicol Sci 98(2):436–444. doi: 10.1093/toxsci/kfm125 · DOI
  55. Hsu EL, Chen N, Westbrook A et al (2008) CXCR4 and CXCL12 down-regulation: a novel mechanism for the chemoprotection of 3,3′-diindolylmethane for breast and ovarian cancers. Cancer Lett 265(1):113–123. doi: 10.1016/j.canlet.2008.02.033 · doi:10.1016/j.canlet.2008.02.033
  56. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR (2007) Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol 71(6):1475–1486 · DOI · Paper page
  57. Huang G, Elferink CJ (2005) Multiple mechanisms are involved in Ah receptor-mediated cell cycle arrest. Mol Pharmacol 67(1):88–96. doi: 10.1124/mol.104.002410 · DOI
  58. Huang TC, Chang HY, Chen CY et al (2011) Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR. FEBS Lett 585(22):3582–3586. doi: 10.1016/j.febslet.2011.10.025 · DOI · Paper page
  59. Iida K, Mimura J, Itoh K et al (2010) Suppression of AhR signaling pathway is associated with the down-regulation of UDP-glucuronosyltransferases during BBN-induced urinary bladder carcinogenesis in mice. J Biochem 147(3):353–360. doi: 10.1093/jb/mvp169 · DOI
  60. Ikuta T, Kobayashi Y, Kitazawa M et al (2013) ASC-associated inflammation promotes cecal tumorigenesis in aryl hydrocarbon receptor-deficient mice. Carcinogenesis 34(7):1620–1627. doi: 10.1093/carcin/bgt083 · DOI · Paper page
  61. Ishida M, Mikami S, Kikuchi E et al (2010) Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 31(2):287–295. doi: 10.1093/carcin/bgp222 · doi:10.1093/carcin/bgp222
  62. Ishida M, Mikami S, Shinojima T et al (2015) Activation of aryl hydrocarbon receptor promotes invasion of clear cell renal cell carcinoma and is associated with poor prognosis and cigarette smoke. Int J Cancer 137(2):299–310. doi: 10.1002/ijc.29398 · DOI
  63. Jaffrain-Rea ML, Angelini M, Gargano D et al (2009) Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer 16(3):1029–1043. doi: 10.1677/ERC-09-0094 · DOI
  64. Jana NR, Sarkar S, Ishizuka M, Yonemoto J, Tohyama C, Sone H (1999) Cross-talk between 2,3,7,8-tetrachlorodibenzo-p-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells. Biochem Biophys Res Commun 256(3):462–468 · DOI
  65. Jin UH, Lee SO, Pfent C, Safe S (2014) The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer 14:498. doi: 10.1186/1471-2407-14-498 · DOI · Paper page
  66. Jin UH, Kim SB, Safe S (2015) Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol 28(5):907–918. doi: 10.1021/tx5005198 · DOI · Paper page
  67. Jordan VC (2007) SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst 99(5):350–356. doi: 10.1093/jnci/djk062 · DOI · Paper page
  68. Jordan VC (2009) A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 69(4):1243–1254. doi: 10.1158/0008-5472.CAN-09-0029 · DOI
  69. Kang HJ, Kim HJ, Kim SK et al (2006) BRCA1 modulates xenobiotic stress-inducible gene expression by interacting with ARNT in human breast cancer cells. J Biol Chem 281(21):14654–14662. doi: 10.1074/jbc.M601613200 · DOI
  70. Kawajiri K, Kobayashi Y, Ohtake F et al (2009) Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc Natl Acad Sci USA 106(32):13481–13486. doi: 10.1073/pnas.0902132106 · DOI · Paper page
  71. Kerkvliet NI, Steppan LB, Vorachek W et al (2009) Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy 1(4):539–547. doi: 10.2217/imt.09.24 · DOI · Paper page
  72. Kim HM, Kim JW, Choi Y et al (2016) Xeno-sensing activity of the aryl hydrocarbon receptor in human pluripotent stem cell-derived hepatocyte-like cells. Sci Rep 6:21684. doi: 10.1038/srep21684 · DOI
  73. Knerr S, Schrenk D (2006) Carcinogenicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in experimental models. Mol Nutr Food Res 50(10):897–907. doi: 10.1002/mnfr.200600006 · DOI · Paper page
  74. Koch DC, Jang HS, O’Donnell EF et al (2015) Anti-androgen flutamide suppresses hepatocellular carcinoma cell proliferation via the aryl hydrocarbon receptor mediated induction of transforming growth factor-beta1. Oncogene 34(50):6092–6104. doi: 10.1038/onc.2015.55 · DOI
  75. Kociba RJ, Keyes DG, Beyer JE et al (1978) Results of a 2-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. Toxicol Appl Pharmacol 46:279–303 · DOI · Paper page
  76. Koliopanus A, Kleeff J, Xiao Y et al (2002) Increased aryl hydrocarbon receptor expression offers a potential therapeutic target in pancreatic cancer. Oncogene 21:6059–6070 · DOI
  77. Kolluri SK, Weiss C, Koff A, Gottlicher M (1999) p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev 13:1742–1753 · DOI · Paper page
  78. Kolluri SK, Balduf C, Hofmann M, Gottlicher M (2001) Novel target genes of the Ah (dioxin) receptor: transcriptional induction of N-myristoyltransferase 2. Cancer Res 61(23):8534–8539
  79. Kuznetsov NV, Andersson P, Gradin K et al (2005) The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis. Oncogene 24(19):3216–3222. doi: 10.1038/sj.onc.1208529 · DOI
  80. Lai DW, Liu SH, Karlsson AI et al (2014) The novel aryl hydrocarbon receptor inhibitor biseugenol inhibits gastric tumor growth and peritoneal dissemination. Oncotarget 5(17):7788–7804. doi: 10.18632/oncotarget.2307 · DOI
  81. le Maire A, Alvarez S, Shankaranarayanan P, Lera AR, Bourguet W, Gronemeyer H (2012) Retinoid receptors and therapeutic applications of RAR/RXR modulators. Curr Top Med Chem 12(6):505–527 · DOI · Paper page
  82. Levine-Fridman A, Chen L, Elferink CJ (2004) Cytochrome P4501A1 promotes G1 phase cell cycle progression by controlling aryl hydrocarbon receptor activity. Mol Pharmacol 65(2):461–469. doi: 10.1124/mol.65.2.461 · DOI
  83. Li ZD, Wang K, Yang XW, Zhuang ZG, Wang JJ, Tong XW (2014) Expression of aryl hydrocarbon receptor in relation to p53 status and clinicopathological parameters in breast cancer. Int J Clin Exp Pathol 7(11):7931–7937
  84. Loaiza-Perez AI, Kenney S, Boswell J et al (2004) Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 3(6):715–725 · DOI · Paper page
  85. Marshall NB, Kerkvliet NI (2010) Dioxin and immune regulation: emerging role of aryl hydrocarbon receptor in the generation of regulatory T cells. Ann N Y Acad Sci 1183:25–37. doi: 10.1111/j.1749-6632.2009.05125.x · DOI · Paper page
  86. Masui K, Gini B, Wykosky J et al (2013) A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis 34(4):725–738. doi: 10.1093/carcin/bgt086 · DOI
  87. McBride DI, Collins JJ, Humphry NF et al (2009) Mortality in workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin at a trichlorophenol plant in New Zealand. J Occup Environ Med 51(9):1049–1056. doi: 10.1097/JOM.0b013e3181b571ae · doi:10.1097/jom.0b013e3181b571ae
  88. McDonnell DP, Wardell SE (2010) The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol 10(6):620–628. doi: 10.1016/j.coph.2010.09.007 · DOI · Paper page
  89. McLean LS, Watkins CN, Campbell P et al (2015) Aryl hydrocarbon receptor ligand 5F 203 induces oxidative stress that triggers DNA damage in human breast cancer cells. Chem Res Toxicol 28(5):855–871. doi: 10.1021/tx500485v · DOI
  90. Moennikes O, Loeppen S, Buchmann A et al (2004) A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res 64(14):4707–4710. doi: 10.1158/0008-5472.CAN-03-0875 · DOI · Paper page
  91. Moore RW, Fritz WA, Schneider AJ et al (2016) 2,3,7,8-Tetrachlorodibenzo-p-dioxin has both pro-carcinogenic and anti-carcinogenic effects on neuroendocrine prostate carcinoma formation in TRAMP mice. Toxicol Appl Pharmacol 305:242–249. doi: 10.1016/j.taap.2016.04.018 · doi:10.1016/j.taap.2016.04.018
  92. Morrow D, Qin C, Smith Iii R, Safe S (2004) Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J Ster Biochem Mol Biol 88:27–36 · DOI
  93. Mulero-Navarro S, Carvajal-Gonzalez JM, Herranz M et al (2006) The dioxin receptor is silenced by promoter hypermethylation in human acute lymphoblastic leukemia through inhibition of Sp1 binding. Carcinogenesis 27(5):1099–1104. doi: 10.1093/carcin/bgi344 · DOI · Paper page
  94. Murray IA, Morales JL, Flaveny CA et al (2010) Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity. Mol Pharmacol 77(2):247–254. doi: 10.1124/mol.109.061788 · DOI
  95. Murray IA, Patterson AD, Perdew GH (2014) Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer 14(12):801–814. doi: 10.1038/Nrc3846 · DOI · Paper page
  96. Nukaya M, Walisser JA, Moran SM, Kennedy GD, Bradfield CA (2010) Aryl hydrocarbon receptor nuclear translocator in hepatocytes is required for aryl hydrocarbon receptor-mediated adaptive and toxic responses in liver. Toxicol Sci 118(2):554–563. doi: 10.1093/toxsci/kfq305 · DOI · Paper page
  97. O’Donnell EF, Kopparapu PR, Koch DC et al (2012) The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PLoS ONE 7(7):e40926. doi: 10.1371/journal.pone.0040926 · DOI
  98. O’Donnell EF, Koch DC, Bisson WH, Jang HS, Kolluri SK (2014) The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells. Cell Death Dis 5:e1038. doi: 10.1038/cddis.2013.549 · DOI · Paper page
  99. Pabst C, Krosl J, Fares I et al (2014) Identification of small molecules that support human leukemia stem cell activity ex vivo. Nat Methods 11(4):436–442. doi: 10.1038/nmeth.2847 · DOI
  100. Parks AJ, Pollastri MP, Hahn ME et al (2014) In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol 86(5):593–608. doi: 10.1124/mol.114.093369 · DOI
  101. Peng TL, Chen J, Mao W, Song X, Chen MH (2009) Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biology 10:27. doi: 10.1186/1471-2121-10-27 · DOI
  102. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi: 10.1038/35021093 · DOI · Paper page
  103. Pesatori AC, Consonni D, Rubagotti M, Grillo P, Bertazzi PA (2009) Cancer incidence in the population exposed to dioxin after the “Seveso accident”: twenty years of follow-up. Environ Health 8:39. doi: 10.1186/1476-069X-8-39 · DOI · Paper page
  104. Portal-Nunez S, Shankavaram UT, Rao M et al (2012) Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice. Cancer Res 72(22):5790–5800. doi: 10.1158/0008-5472.CAN-12-0818 · DOI
  105. Prud’homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V, Jothy S (2010) Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS ONE 5(11):e13831. doi: 10.1371/journal.pone.0013831 · DOI · Paper page
  106. Punj S, Kopparapu P, Jang HS et al (2014) Benzimidazoisoquinolines: a new class of rapidly metabolized aryl hydrocarbon receptor (AhR) ligands that induce AhR-dependent Tregs and prevent murine graft-versus-host disease. PLoS ONE 9(2):e88726. doi: 10.1371/journal.pone.0088726 · DOI
  107. Rentas S, Holzapfel NT, Belew MS et al (2016) Musashi-2 attenuates AHR signalling to expand human haematopoietic stem cells. Nature 532(7600):508–511. doi: 10.1038/nature17665 · DOI · Paper page
  108. Richmond O, Ghotbaddini M, Allen C, Walker A, Zahir S, Powell JB (2014) The aryl hydrocarbon receptor is constitutively active in advanced prostate cancer cells. PLoS ONE 9(4):e95058. doi: 10.1371/journal.pone.0095058 · DOI
  109. Rignall B, Grote K, Gavrilov A et al (2013) Biological and tumor-promoting effects of dioxin-like and non-dioxin-like polychlorinated biphenyls in mouse liver after single or combined treatment. Toxicol Sci 133(1):29–41. doi: 10.1093/toxsci/kft034 · doi:10.1093/toxsci/kft034
  110. Ronnekleiv-Kelly SM, Nukaya M, Diaz-Diaz CJ et al (2016) Aryl hydrocarbon receptor-dependent apoptotic cell death induced by the flavonoid chrysin in human colorectal cancer cells. Cancer Lett 370(1):91–99. doi: 10.1016/j.canlet.2015.10.014 · DOI
  111. Safe S, Qin C, McDougal A (1999) Development of selective aryl hydrocarbon receptor modulators (SAhRMs) for treatment of breast cancer. Expert Opin Investig Drugs 8:1385–1396 · DOI
  112. Safe S, Chadalapaka G, Jutooru I (2012) AHR-reactive compounds in the human diet. In: Pohjanvirta R (ed) The Ah receptor in biology and toxicology. Wiley, Hoboken, pp 331–342
  113. Safe S, Lee SO, Jin UH (2013) Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol Sci 135(1):1–16. doi: 10.1093/toxsci/kft128 · DOI · Paper page
  114. Sanchez-Martin FJ, Fernandez-Salguero PM, Merino JM (2010) 2,3,7,8-Tetrachlorodibenzo-p-dioxin induces apoptosis in neural growth factor (NGF)-differentiated pheochromocytoma PC12 cells. Neurotoxicology 31(3):267–276. doi: 10.1016/j.neuro.2010.03.005 · DOI
  115. Santagata S, Thakkar A, Ergonul A et al (2014) Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest 124(2):859–870. doi: 10.1172/JCI70941 · DOI · Paper page
  116. Schreck I, Deigendesch U, Burkhardt B, Marko D, Weiss C (2012) The Alternaria mycotoxins alternariol and alternariol methyl ether induce cytochrome P450 1A1 and apoptosis in murine hepatoma cells dependent on the aryl hydrocarbon receptor. Arch Toxicol 86(4):625–632. doi: 10.1007/s00204-011-0781-3 · DOI
  117. Shah I, Houck K, Judson RS et al (2011) Using nuclear receptor activity to stratify hepatocarcinogens. PLoS ONE 6(2):e14584. doi: 10.1371/journal.pone.0014584 · DOI
  118. Shimba S, Komiyama K, Moro I, Tezuka M (2002) Overexpression of the aryl hydrocarbon receptor (AhR) accelerates the cell proliferation of A549 cells. J Biochem 132(5):795–802 · DOI
  119. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics. CA Cancer J Clin 65(1):5–29. doi: 10.3322/caac.21254 · DOI · Paper page
  120. Silginer M, Burghardt I, Gramatzki D et al (2016) The aryl hydrocarbon receptor links integrin signaling to the TGF-beta pathway. Oncogene 35(25):3260–3271. doi: 10.1038/onc.2015.387 · DOI
  121. Singh KP, Wyman A, Casado FL, Garrett RW, Gasiewicz TA (2009) Treatment of mice with the Ah receptor agonist and human carcinogen dioxin results in altered numbers and function of hematopoietic stem cells. Carcinogenesis 30(1):11–19. doi: 10.1093/carcin/bgn224 · DOI
  122. Sinn HP, Kreipe H (2013) A brief overview of the WHO classification of breast tumors, 4th Edition, focusing on issues and updates from the 3rd Edition. Breast Care 8(2):149–154. doi: 10.1159/000350774 · DOI · Paper page
  123. Stanford EA, Ramirez-Cardenas A, Wang Z et al (2016a) Role for the aryl hydrocarbon receptor and diverse ligands in oral squamous cell carcinoma migration and tumorigenesis. Mol Cancer Res 14(8):696–706. doi: 10.1158/1541-7786.MCR-16-0069 · DOI · Paper page
  124. Stanford EA, Wang Z, Novikov O et al (2016b) The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells. BMC Biol 14:20. doi: 10.1186/s12915-016-0240-y · DOI
  125. Su Y, Zeng Z, Zhang W, Chen Z, Xu D, Zhang XK (2016) Recent progress in the design and discovery of RXR modulators targeting alternate binding sites of the receptor. Curr Top Med Chem 16:1–13
  126. Sun F, Indran IR, Zhang ZW et al (2015) A novel prostate cancer therapeutic strategy using Icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants. Carcinogenesis 36(7):757–768. doi: 10.1093/carcin/bgv040 · DOI
  127. Tice CM, Zheng YJ (2016) Non-canonical modulators of nuclear receptors. Bioorg Med Chem Lett 26(17):4157–4164. doi: 10.1016/j.bmcl.2016.07.067 · DOI
  128. To KK, Yu L, Liu S, Fu J, Cho CH (2012) Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells. Mol Carcinog 51(6):449–464. doi: 10.1002/mc.20810 · DOI
  129. Tomblin JK, Salisbury TB (2014) Insulin like growth factor 2 regulation of aryl hydrocarbon receptor in MCF-7 breast cancer cells. Biochem Biophys Res Commun 443(3):1092–1096. doi: 10.1016/j.bbrc.2013.12.112 · DOI
  130. Tompkins LM, Li H, Li L et al (2010) A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. Biochem Pharmacol 80(11):1754–1761. doi: 10.1016/j.bcp.2010.08.016 · DOI · Paper page
  131. Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev 25(1):16–27. doi: 10.1158/1055-9965.EPI-15-0578 · DOI · Paper page
  132. Tran C, Richmond O, Aaron L, Powell JB (2013) Inhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells. Biochem Pharmacol 85(6):753–762. doi: 10.1016/j.bcp.2012.12.010 · DOI
  133. Tsai CF, Hsieh TH, Lee JN et al (2015) Curcumin suppresses phthalate-induced metastasis and the proportion of cancer stem cell (CSC)-like cells via the inhibition of AhR/ERK/SK1 signaling in hepatocellular carcinoma. J Agric Food Chem 63(48):10388–10398. doi: 10.1021/acs.jafc.5b04415 · DOI
  134. Viale G (2012) The current state of breast cancer classification. Ann Oncol 23(Suppl 10):x207–x210. doi: 10.1093/annonc/mds326 · DOI · Paper page
  135. Villano CM, Murphy KA, Akintobi A, White LA (2006) 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces matrix metalloproteinase (MMP) expression and invasion in A2058 melanoma cells. Toxicol Appl Pharmacol 210(3):212–224. doi: 10.1016/j.taap.2005.05.001 · DOI
  136. Villard PH, Caverni S, Baanannou A et al (2007) PPARa transcriptionally induces AhR expression in Caco-2, but represses AhR pro-inflammatory effects. Biochem Biophys Res Commun 364(4):896–901. doi: 10.1016/j.bbrc.2007.10.084 · doi:10.1016/j.bbrc.2007.10.084
  137. Vogel CF, Li W, Sciullo E et al (2007) Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression. Am J Pathol 171(5):1538–1548. doi: 10.2353/ajpath.2007.070406 · DOI
  138. Volkov MS, Bolotina NA, Evteev VA, Koblyakov VA (2012) Ah-receptor-independent stimulation of hepatoma 27 culture cell proliferation by polycyclic aromatic hydrocarbons. Biochemistry 77(2):201–207. doi: 10.1134/S0006297912020125 · doi:10.1134/s0006297912020125
  139. Wang CK, Chang H, Chen PH et al (2009) Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas. Int J Cancer 125(4):807–815. doi: 10.1002/ijc.24348 · DOI
  140. Wang T, Gavin HM, Arlt VM et al (2011a) Aryl hydrocarbon receptor activation during pregnancy, and in adult nulliparous mice, delays the subsequent development of DMBA-induced mammary tumors. Int J Cancer 128(7):1509–1523. doi: 10.1002/ijc.25493 · DOI
  141. Wang T, Wyrick KL, Meadows GG, Wills TB, Vorderstrasse BA (2011b) Activation of the aryl hydrocarbon receptor by TCDD inhibits mammary tumor metastasis in a syngeneic mouse model of breast cancer. Toxicol Sci 124(2):291–298. doi: 10.1093/toxsci/kfr247 · DOI
  142. Weiss C, Kolluri SK, Kiefer F, Gottlicher M (1996) Complementation of Ah receptor deficiency in hepatoma cells: negative feedback regulation and cell cycle control by the Ah receptor. Exp Cell Res 226(1):154–163. doi: 10.1006/excr.1996.0214 · DOI · Paper page
  143. Weiss C, Faust D, Durk H et al (2005) TCDD induces c-jun expression via a novel Ah (dioxin) receptor-mediated p38-MAPK-dependent pathway. Oncogene 24(31):4975–4983. doi: 10.1038/sj.onc.1208679 · DOI
  144. Xie G, Peng Z, Raufman JP (2012) Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am J Physiol Gastrointest Liver Physiol 302(9):G1006–G1015. doi: 10.1152/ajpgi.00427.2011 · DOI · Paper page
  145. Yin XF, Chen J, Mao W, Wang YH, Chen MH (2012) A selective aryl hydrocarbon receptor modulator 3,3′-diindolylmethane inhibits gastric cancer cell growth. J Exp Clin Cancer Res 31:46. doi: 10.1186/1756-9966-31-46 · DOI
  146. Yin XF, Chen J, Mao W, Wang YH, Chen MH (2013) Downregulation of aryl hydrocarbon receptor expression decreases gastric cancer cell growth and invasion. Oncol Rep 30(1):364–370. doi: 10.3892/or.2013.2410 · DOI
  147. Yin J, Sheng B, Han B et al (2016) The AhR is involved in the regulation of LoVo cell proliferation through cell cycle-associated proteins. Cell Biol Int 40(5):560–568. doi: 10.1002/cbin.10592 · DOI
  148. Zhang S, Lei P, Liu X et al (2009) The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy. Endocr Relat Cancer 16(3):835–844. doi: 10.1677/ERC-09-0054 · DOI · Paper page
  149. Zhang J, Zong H, Li S, Zhang D, Zhang L, Xia Q (2012a) Activation of aryl hydrocarbon receptor suppresses invasion of esophageal squamous cell carcinoma cell lines. Tumori 98(1):152–157. doi: 10.1700/1053.11514 · doi:10.1700/1053.11514
  150. Zhang S, Kim K, Jin UH et al (2012b) Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells. Mol Cancer Ther 11(1):108–118. doi: 10.1158/1535-7163.MCT-11-0548 · DOI
  151. Zhao QW, Zhou YW, Li WX et al (2015) Akt-mediated phosphorylation of Oct4 is associated with the proliferation of stemlike cancer cells. Oncol Rep 33(4):1621–1629. doi: 10.3892/or.2015.3752 · DOI

Cited by

See all 173

Metadata

Authors
Kolluri, S. K., Jin, U.-H., & Safe, S.
Venue
Archives of Toxicology
Published
2017-05-15
Volume
91
Issue
7
Pages
2497-2513
ISSN
  • 0340-5761 (ISSN-L)
  • 1432-0738
OpenAlex
W2614737589
Cited by
173
References
20
FWCI
9.97
Type
journal article
Language
en
Update notices
erratum (2017-07-11)
Open access
green
Licence
Funders
  • National Institute of Environmental Health Sciences (P30-ES023512, R01-ES025839)
  • National Cancer Institute (R01-CA202697)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.